A Phase II study of NBI-74788 for the treatment of pediatric congenital adrenal hyperplasia (CAH)
Phase of Trial: Phase II
Latest Information Update: 06 Jan 2019
At a glance
- Drugs NBI 74788 (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Therapeutic Use
- 06 Jan 2019 According to a Neurocrine Biosciences media release, initiation of the trial is expected in Q2/Q3 2019.
- 10 Jan 2018 New trial record
- 07 Jan 2018 According to a Neurocrine Biosciences media release, the company plans to initiate this study in 2H 2018.